Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dewpoint Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://dewpointx.com/
Year Founded: 2018
Status: Private
BioCentury | Dec 10, 2024
Deals
Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar
Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
BioCentury | Sep 14, 2023
Regulation
Sept. 13 Quick Takes: Madrigal gets March PDUFA date for NASH therapy
Plus: Rocket parlays gene therapy update into $175M raise and updates from DalCor, Mironid, Crinetics, Shionogi, Hasten, Dewpoint and Orchid
BioCentury | Mar 23, 2023
Deals
March 23 Quick Takes: Moderna, Generation Bio in non-viral genetic medicines pact
Plus: PureTech sells royalty for Karuna’s schizophrenia asset and updates from Dewpoint, Novo Nordisk, Gilead and more
BioCentury | Feb 24, 2023
Emerging Company Profile
Paratus: leveraging bat biology to improve human health
Biotech has raised $100M to industrialize bat biology
BioCentury | Nov 1, 2022
Emerging Company Profile
HI-Bio: pairing immune cell-targeting approach with deal to drive clinical work
Backed by Arch, Monograph and Jeito with $120M, the immunology company has jump-started its clinical plan via a deal with MorphoSys
BioCentury | Oct 25, 2022
Management Tracks
Williamson made president and CBO of Triumvira
Plus new heads of strategy, CMC at Actinium, and updates from Telegraph Hill and Sebela
BioCentury | Sep 20, 2022
Management Tracks
Luo joins Everest as CEO
Plus Hitchcock named CSO at Takeda, and updates from Viracta, Agios, Aktis and more
BioCentury | Jun 14, 2022
Deals
Arch, Monograph-backed HI-Bio builds pipeline with MorphoSys deal
German biotech offloads rights to pair of programs with potential in immunology, tightens focus on oncology
BioCentury | Feb 12, 2022
Data Byte
Investments by Leaps by Bayer
Bayer’s investment arm has backed 18 venture rounds since 2021
BioCentury | Feb 8, 2022
Finance
Feb. 7 Quick Takes: WuXi Biologics shares fall after landing on Commerce list
Plus mega-rounds for Endeavor, Dewpoint and updates from Koneksa, ObsEva and more
Items per page:
1 - 10 of 20